Connect Biopharma Holdings Limited announced on February 12, 2024, the appointment of James Zuie-chin Huang, M.B.A., as a new member of its Board of Directors. Huang brings over three decades of biotech experience to the table, having founded Panacea Venture and served in senior roles at various prestigious firms and companies, including Kleiner Perkins China, Vivo Ventures, and Anesiva, Inc. His previous board memberships include Casi Pharmaceuticals, Windtree Therapeutics, and Alaunos Therapeutics, and he currently serves on the board of Kindstar Globalgene Technology. Huang's educational background includes an M.B.A. from Stanford and a B.S. in chemical engineering from UC Berkeley. The Board has confirmed Huang as an independent director per Nasdaq's listing requirements, and he has entered into the company's standard Indemnification Agreement. There are no disclosed arrangements or transactions involving Huang that would necessitate disclosure under SEC regulations.

Connect Biopharma Holdings Limited announced on February 12, 2024, the appointment of James Zuie-chin Huang, M.B.A., as a new member of its Board of Directors. Huang brings over three decades of biotech experience to the table, having founded Panacea Venture and served in senior roles at various prestigious firms and companies, including Kleiner Perkins China, Vivo Ventures, and Anesiva, Inc. His previous board memberships include Casi Pharmaceuticals, Windtree Therapeutics, and Alaunos Therapeutics, and he currently serves on the board of Kindstar Globalgene Technology. Huang's educational background includes an M.B.A. from Stanford and a B.S. in chemical engineering from UC Berkeley. The Board has confirmed Huang as an independent director per Nasdaq's listing requirements, and he has entered into the company's standard Indemnification Agreement. There are no disclosed arrangements or transactions involving Huang that would necessitate disclosure under SEC regulations.